Author:
D’Amico Lucia,Menzel Ulrike,Prummer Michael,Müller Philipp,Buchi Mélanie,Kashyap Abhishek,Haessler Ulrike,Yermanos Alexander,Gébleux Rémy,Briendl Manfred,Hell Tamara,Wolter Fabian I.,Beerli Roger R.,Truxova Iva,Radek Špíšek,Vlajnic Tatjana,Grawunder Ulf,Reddy Sai,Zippelius Alfred
Subject
Cancer Research,Pharmacology,Oncology,Molecular Medicine,Immunology,Immunology and Allergy
Reference34 articles.
1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177–82.
2. Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol Proc Am Soc Clin Oncol. 2010;28:92–8.
3. Hudis CA. Trastuzumab--mechanism of action and use in clinical practice. N Engl J Med. 2007;357:39–51.
4. Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. American Association for Cancer Research. 2008;68:9280–90.
5. Krop IE, Kim S-B, González-Martín A, LoRusso PM, Ferrero J-M, Smitt M, et al. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15:689–99.
Cited by
77 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献